Russell Briggs, MD
Otolaryngology/Facial Plastic Surgery · Austin, TXNPI 1942245196
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 340 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,578, 3.8 times the $687 reported in 2019.
Across 340 payments — averaging $25.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- Sanofi$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Optinose US, Inc.$660
- Stryker$593
- Acclarent, Inc$451
- plus $3K from 19 others
What the payments were for
- Consulting fees$1952%
- Food & beverage$8,55498%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 49 | $1,777 |
| Sanofi | 68 | $1,378 |
| Regeneron Healthcare Solutions, Inc. | 60 | $1,317 |
| Optinose US, Inc. | 45 | $660 |
| Stryker | 15 | $593 |
| Acclarent, Inc | 22 | $451 |
| Medtronic(2 entities) | 8 | $417 |
| GSK | 27 | $416 |
| Aerin Medical Inc. | 15 | $405 |
| Carestream Dental, LLC | 1 | $373 |
| Integra Lifesciences Corporation | 3 | $367 |
| AbbVie | 4 | $144 |
| Hikma Pharmaceuticals USA | 4 | $73 |
| Itamar Medical Inc | 2 | $61 |
| AstraZeneca | 3 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $48 |
| Greer Laboratories, Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $36 |
| Pfizer | 2 | $28 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Olympus America Inc. | 1 | $17 |
| Xoran Technologies LLC | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire Upper Airway Stimulation System$547
- Acclarent Aera$320
- Inspira Air$320
- RELIEVA SPINPLUS NAV$320
- TruDi Probe$320
- ENTELLUS - ENTELLUS MEDICAL SHAVER SYSTEM$160
- ENTELLUS - FIAGON SINUS NAVIGATION SYSTEM$160
- ENTELLUS - XPRESS ENT DILATION SYSTEM$160
- Inspire$153
- VIVAER STYLUS$148
- RHINAER STYLUS$148
- DUPIXENT$124
How this compares
$8,749 in reported general payments places this provider in the 80th percentile of 51 otolaryngology/facial plastic surgery providers in Texas.
See all otolaryngology/facial plastic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 11 | $93,168 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $11,443 |
| QnaslBeclomethasone Dipropionate | 15 | $9,464 |
| Ipratropium Bromide | 283 | $9,216 |
| DuleraMometasone/Formoterol | 11 | $3,579 |
| Epinephrine | 14 | $3,304 |
| Fluticasone Propionate | 131 | $1,707 |
| Pantoprazole Sodium | 189 | $1,550 |
| Fluocinolone Acetonide Oil | 38 | $1,389 |
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 19 | $1,336 |
| Pilocarpine Hcl | 28 | $1,219 |
| Azelastine Hcl | 39 | $1,109 |
| Levocetirizine Dihydrochloride | 50 | $877 |
| Famotidine | 34 | $500 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 54 | $448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $416 | $11,44311 claims |
| Hikma Pharmaceuticals USAEpinephrine | $73 | $3,30414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 51 otolaryngology/facial plastic surgery providers in Texas.
Other otolaryngology/facial plastic surgery in Austin
- Yula IndeyevaAustin$579K
- Minas ConstantinidesAustin$7K
- Melissa BenderAustin$285
- James HicksAustin$16
- Manuel LopezSan Antonio$55K
- Michel SiegelHouston$23K
- Etai FunkHouston$18K
- Jamie KuHouston$18K
- James AndrewsHouston$11K
- Daniel LeemanGeorgetown$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.